Sign in

Alissandra Hillis

@alissandra-hillis.bsky.social
57 followers 73 following 0 posts

Postdoctoral researcher at MIT @mvhlab.bsky.social Alum of MIT 5-7 and Harvard BBS @alextoker.bsky.social she/her

PostsRepliesMedia
Reposted by Alissandra Hillis
Eddie Rashan @edreesrashan.bsky.social · 23/06/2025
AND IT'S DONE! A 🧵 on our recent article now out in @natsmb.nature.com! Co-led with @abbybartlett.bsky.social, Pagliarini Lab, @judisimcox.bsky.social, we find ACAD10/11 are NOT like other acyl-CoA dehydrogenases and instead catabolize atypical lipids called 4-hydroxy acids 🤯 doi.org/10.1038/s415...
doi.org
ACAD10 and ACAD11 enable mammalian 4-hydroxy acid lipid catabolism - Nature Structural & Molecular Biology
Rashan, Bartlett and colleagues show that mammalian 4-hydroxy fatty acids are primarily catabolized by ACAD10 and ACAD11 (atypical mitochondrial and peroxisomal acyl-CoA dehydrogenases, respectively) ...
23619
Reposted by Alissandra Hillis
Vander Heiden Lab at MIT @mvhlab.bsky.social · 14/03/2025
Happy Pi Day! MVH Lab's two delicious contributions to Pi day:
0144
Reposted by Alissandra Hillis
Vander Heiden Lab at MIT @mvhlab.bsky.social · 23/11/2024
Looking at human kidney cancer, we profiled nutrient levels in the tumor environment and found they are similar to nutrient levels in healthy kidney tissue, suggesting tumors must work within constraints of nutrients available rather than change nutrient environment. elifesciences.org/articles/95652
elifesciences.org
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability
Assessing metabolites in renal cell carcinoma and kidney tissue suggests cancers adapt rather than dictate nutrient availability.
0253
Reposted by Alissandra Hillis
Alex Toker @alextoker.bsky.social · 20/11/2024
Published a few weeks ago in Cancer Research, we show benefit of targeting HMCR with pitavastatin in combo with AKT inhibitors in TNBC. Many amazing people contributed, led by the magnificently talented @alissandra-hillis.bsky.social! Looking to initiate new clinical trials based on this combo. 🧪
aacrjournals.org
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer
Two FDA-approved compounds, AKT inhibitors and pitavastatin, synergize to induce cell death in triple-negative breast cancer, motivating evaluation of the efficacy of this combination in clinical tria...
05617
Reposted by Alissandra Hillis
Alex Toker @alextoker.bsky.social · 17/11/2024
Great to be posting science again!! Very proud of this work, thanks to a wonderful collaboration with Forest White lab at MIT, Cantley lab at DFCI, and leb by the amazingly talented @alissandra-hillis.bsky.social! Published as fully @openaccess.bsky.social in PNAS. www.pnas.org/doi/10.1073/...
17716